Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Lynparza (olaparib) may become standard follow-up therapy for women with newly diagnosed ovarian cancer that has a BRCA mutation.
We have heard again and again that women are eager for more information, not less. And they want to do everything they can to stay healthy.
New database provides information on gene variants to clinicians, researchers and patient advocates around the world.
HBOC Week recognizes anyone affected by hereditary breast, ovarian and related cancers.
PARP inhibitor slowed disease progression in clinical study.
The PARP inhibitor Lynparza slows disease progression in women with BRCA-related ovarian cancer.
The drug, a PARP inhibitor, blocks proteins that help repair damaged DNA, and so can cause tumor cells that carry a BRCA mutation to die.
In tumors with missing or mutated BRCA genes, PARP inhibitors plus other drugs have worked well—but the cancer often becomes drug-resistant.
New study finds that simple cysts should be considered normal and ignored.
Physicians recognize that ovarian cancer isn’t a single disease but a group of related disorders with distinct genetic and cellular features
PARP inhibitor demonstrates unprecedented improvement in progression-free survival.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.